Capricor Therapeutics Inc (CAPR) (Q3 2026) Earnings Call Highlights: Deramiocel Nears PDUFA ...
Capricor Therapeutics Inc (CAPR) reported no Q3 2026 revenue but ended the quarter with approximately $198.5 million in cash and securities as it awaits a November 22, 2026 PDUFA date for Deramiocel. Related Stocks: CAPR ,